Crestor · DIN 02265540 · 5 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Savings card: innoviCares lists Crestor (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists CRESTOR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, September 10, 2026 ↗)
1 brand, same coverage
Crestor · DIN 02265540
Manufacturer: AstraZeneca; listing date 2007-01-02
Health Canada: Marketed since 2005-03-18 · brand CRESTOR - 5MG · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Astrazeneca canada inc · schedule Prescription
Ministry pays: $0.1284 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02265540)
Source record
DIN 02265540: Crestor
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id AZC
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.5177; ministry $0.1284
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02265540
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75100
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284
Apo-Rosuvastatin · DIN 02337975 · $0.1284
Auro-Rosuvastatin · DIN 02442574 · $0.1284
Bio-Rosuvastatin · DIN 02444968 · $0.1284
Co Rosuvastatin · DIN 02339765 · $0.1284
Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284
Jamp-Rosuvastatin · DIN 02391252 · $0.1284
M-Rosuvastatin · DIN 02496534 · $0.1284
Mar-Rosuvastatin · DIN 02413051 · $0.1284
Med-Rosuvastatin · DIN 02399164 · $0.1284
Mint-Rosuvastatin · DIN 02397781 · $0.1284
NRA-Rosuvastatin · DIN 02477483 · $0.1284
NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284
PMS-Rosuvastatin · DIN 02378523 · $0.1284
PRZ-Rosuvastatin · DIN 02505576 · $0.1284
Rosuvastatin · DIN 02405628 · $0.1284
Rosuvastatin · DIN 02411628 · $0.1284
Sandoz Rosuvastatin · DIN 02338726 · $0.1284
Taro-Rosuvastatin · DIN 02382644 · $0.1284
Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02265540
Shortage record checked October 6, 2026